These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 9872360)

  • 21. Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium.
    Gomes MK; Rosa-e-Silva JC; Garcia SB; de Sá Rosa-e-Silva AC; Turatti A; Vieira CS; Ferriani RA
    Hum Reprod; 2009 Nov; 24(11):2736-45. PubMed ID: 19661125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis.
    Laoag-Fernandez JB; Maruo T; Pakarinen P; Spitz IM; Johansson E
    Hum Reprod; 2003 Apr; 18(4):694-9. PubMed ID: 12660258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium.
    Charnock-Jones DS; Macpherson AM; Archer DF; Leslie S; Makkink WK; Sharkey AM; Smith SK
    Hum Reprod; 2000 Aug; 15 Suppl 3():85-95. PubMed ID: 11041225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women.
    Morison NB; Zhang J; Kaitu'u-Lino TJ; Fraser IS; Salamonsen LA
    Reproduction; 2007 Jan; 133(1):309-21. PubMed ID: 17244756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo.
    Greb RR; Heikinheimo O; Williams RF; Hodgen GD; Goodman AL
    Hum Reprod; 1997 Jun; 12(6):1280-92. PubMed ID: 9222018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine system.
    Möller B; Rönnerdag M; Wang G; Odlind V; Olovsson M
    Hum Reprod; 2005 May; 20(5):1410-7. PubMed ID: 15760960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endometrial effects of intrauterine levonorgestrel.
    Guttinger A; Critchley HO
    Contraception; 2007 Jun; 75(6 Suppl):S93-8. PubMed ID: 17531624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen.
    Philip S; Taylor AH; Konje JC; Habiba M
    J Obstet Gynaecol; 2019 Nov; 39(8):1117-1122. PubMed ID: 31195902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coexpression of fractalkine and its receptor in normal human endometrium and in endometrium from users of progestin-only contraception supports a role for fractalkine in leukocyte recruitment and endometrial remodeling.
    Hannan NJ; Jones RL; Critchley HO; Kovacs GJ; Rogers PA; Affandi B; Salamonsen LA
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6119-29. PubMed ID: 15579768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium.
    Roopa BA; Loganath A; Singh K
    Hum Reprod; 2003 Sep; 18(9):1809-19. PubMed ID: 12923132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception.
    Jones RL; Salamonsen LA; Critchley HO; Rogers PA; Affandi B; Findlay JK
    Mol Hum Reprod; 2000 Dec; 6(12):1107-17. PubMed ID: 11101694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study.
    Wildemeersch D; Schacht E
    Maturitas; 2000 Jul; 36(1):63-8. PubMed ID: 10989243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between c-fos and c-jun expression and estrogen and progesterone receptors is lost in human endometrial cancer.
    Salmi A; Carpén O; Rutanen E
    Tumour Biol; 1999; 20(4):202-11. PubMed ID: 10393530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism?
    Mandelin E; Koistinen H; Koistinen R; Affandi B; Seppälä M
    Hum Reprod; 1997 Dec; 12(12):2671-5. PubMed ID: 9455833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
    Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
    Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: essential differences and perspectives.
    Goldstuck ND
    Eur J Contracept Reprod Health Care; 2023 Jun; 28(3):177-183. PubMed ID: 37042204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.